SCHEMBL7073064

SCHEMBL7073064

Fc1ccc(OCCCN2CC3CC(c4ccc(F)cc4)C3C2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 5/20 0.50
DRD2 P14416 5/20 0.50
HTR2A P28223 5/20 0.50
DRD3 P35462 5/20 0.50
DRD1 P21728 3/20 0.50
DRD5 P21918 2/20 0.50
HTT P42858 2/20 0.47
MEN1 O00255 1/20 0.47
LMNA P02545 1/20 0.47
KMT2A Q03164 1/20 0.47
HRH3 Q9Y5N1 2/20 0.46
USP2 O75604 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
KDM4E B2RXH2 1/20 0.46
SIGMAR1 Q99720 2/20 0.45
HRH1 P35367 2/20 0.45
TMEM97 Q5BJF2 1/20 0.45
HTR5A P47898 1/20 0.44
HTR7 P34969 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7071917 0.94 KDM1A (0.51) HTR1ADRD2HTR2ADRD3DRD1
SCHEMBL7076875 0.94 LTA4H (0.48) HTR1ADRD2HTR2ADRD3DRD1
SCHEMBL7076338 0.91 HRH3 (0.49) HTR1ADRD2HTR2ADRD3DRD1
SCHEMBL7078780 0.82 MEN1 (0.51) HTR2ADRD3MEN1KMT2AHRH3
SCHEMBL7781178 0.81 KDM1A (0.45) HTR1ADRD2HTR2ADRD3DRD1
SCHEMBL8989718 0.80 KDM1A (0.39) DRD2HTR2AHTR2BKDM1A
SCHEMBL7480872 0.80 KDM1A (0.39) DRD2HTR2AHTR2BKDM1A
SCHEMBL7073067 0.80 KDM1A (0.39) DRD2HTR2AHTR2BKDM1A
SCHEMBL9010705 0.80 SCN5A (0.44) HTR1ADRD2HTR2ADRD3DRD1
SCHEMBL8989703 0.79 SLC18A3 (0.47) DRD2DRD3LMNAKDM4ESIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0740658-B1 N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USED, FOR EXAMPLE, AS NEUROLEPTICS ABBOTT GMBH & CO KG (DE) 2003-07-02 EP disclosed
EP-1133293-A1 USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM BASF AKTIENGESELLSCHAFT (DE) 2001-09-19 EP disclosed
WO-2000030639-A1 USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM BASF AKTIENGESELLSCHAFT (DE) 2000-06-02 WO disclosed
US-5616705-A N-substituted azabicycloheptane derivatives, their preparation and use BASF AKTIENGESELLSCHAFT (DE) 1997-04-01 US disclosed
EP-0740658-A1 N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USED, FOR EXAMPLE, AS NEUROLEPTICS BASF AKTIENGESELLSCHAFT (DE) 1996-11-06 EP disclosed
WO-1995015312-A1 N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USED, FOR EXAMPLE, AS NEUROLEPTICS BASF AKTIENGESELLSCHAFT (DE) 1995-06-08 WO disclosed